Moleculin Biotech, Inc. (MBRX) Revenue History
Annual and quarterly revenue from 2015 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MBRX Revenue Growth
MBRX Revenue Analysis (2015–2025)
As of May 8, 2026, Moleculin Biotech, Inc. (MBRX) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, MBRX's historical revenue data shows various trends over time.
When compared to Healthcare sector peers including SNDX (+396.7% YoY), AGIO (+78.3% YoY), and TPVG. Compare MBRX vs SNDX →
MBRX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MBRXCurrent | $0 | - | - | - | |
 SNDX | $172M | +396.7% | +157.7% | -158.4% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 TPVG | $97M | - | - | 77.9% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% |
MBRX Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-90,000 | - | $-25,103,000 | - |
| 2024 | $0 | - | $0 | - | $-26,641,000 | - |
| 2023 | $0 | - | $0 | - | $-29,631,000 | - |
| 2022 | $0 | - | $0 | - | $-30,640,000 | - |
| 2021 | $0 | - | $0 | - | $-22,968,000 | - |
| 2020 | $0 | - | $0 | - | $-19,742,000 | - |
| 2019 | $0 | - | $-185,000 | - | $-17,524,000 | - |
| 2018 | $0 | - | $-68,000 | - | $-15,025,000 | - |
| 2017 | $0 | - | $-18,000 | - | $-8,653,000 | - |
| 2016 | $0 | - | $-6,162 | - | $-3,883,147 | - |
See MBRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MBRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MBRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMBRX — Frequently Asked Questions
Quick answers to the most common questions about buying MBRX stock.
Is MBRX's revenue growth accelerating or slowing?
MBRX TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is MBRX's long-term revenue growth rate?
Moleculin Biotech, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is MBRX's revenue distributed by segment?
MBRX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2015-2025 are available for download. Segment mix reveals concentration and diversification trends.